Ravulizumab in Pregnancies Complicated by Severe Hypertensive Disorders
Launched by MAYO CLINIC · Mar 20, 2024
Trial Information
Current as of July 24, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a medication called ravulizumab to see if it can help women who are experiencing severe preeclampsia or HELLP syndrome during pregnancy. Preeclampsia is a serious condition that can happen after the 20th week of pregnancy and can affect both the mother and the baby. The researchers are looking for women who are between 6 and 34 weeks pregnant and have been diagnosed with these conditions to participate in the study.
To be eligible, women must be experiencing severe preeclampsia or HELLP features and be less than 34 weeks pregnant. However, there are some criteria that would exclude someone from the trial, such as having certain serious health issues or complications with the baby. Participants in the trial will receive the study medication and be monitored closely by healthcare professionals. This research aims to find out if ravulizumab can provide a safer option for managing these severe pregnancy complications.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Individuals with \< 34 0/7 weeks of gestation.
- • Individuals with severe preeclampsia or HELLP features.
- Exclusion Criteria:
- • Pregnant female patients presenting with disseminated intravascular coagulopathy (DIC).
- • Individuals with non-reassuring fetal status requiring delivery, non-viable fetuses, previable pregnancy (\<23 0/7 weeks gestation), stroke, in utero fetal demise, known atypical hemolytic uremic syndrome, familial or acquired thrombocytopenia purpura, paroxysmal nocturnal hemoglobinuria, allergy to Ravulizumab, inability or unwillingness to sign informed consent.
About Mayo Clinic
Mayo Clinic is a renowned nonprofit medical practice and research institution dedicated to providing comprehensive healthcare and advancing medical knowledge through innovative research and education. With a commitment to patient-centered care, Mayo Clinic conducts numerous clinical trials aimed at exploring new therapies and improving treatment outcomes across various disciplines. Leveraging a multidisciplinary approach, the institution collaborates with leading experts and cutting-edge technology to ensure rigorous scientific standards and ethical practices in all its research endeavors. Through its trials, Mayo Clinic seeks to translate breakthroughs in science into tangible benefits for patients, fostering advancements in medicine that enhance health and quality of life.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Rochester, Minnesota, United States
Patients applied
Trial Officials
Maria Lourdes Gonzalez Suarez, MD, PhD
Principal Investigator
Mayo Clinic
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported